Form 8-K - Current report:
SEC Accession No. 0000950170-25-084820
Filing Date
2025-06-11
Accepted
2025-06-11 16:01:45
Documents
10
Period of Report
2025-06-10
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K aldx-20250610.htm   iXBRL 8-K 91016
  Complete submission text file 0000950170-25-084820.txt   205884

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20250610.xsd EX-101.SCH 30864
12 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20250610_htm.xml XML 4712
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251039876
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)